ArticleAntimicrobial agents and chemotherapy2018
Insight into the Significance of Aspergillus fumigatus cyp51A Polymorphisms.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Antifungal Susceptibility andMicroorganisms · 2026Article
- Article
- Genotype-Phenotype Relationships in Azole-ResistantJournal of fungi (Basel, Switzerland) · 2026Review
- Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance.The Journal of antimicrobial chemotherapy · 2026Article
- First Report of Human Infection Caused by Aspergillus steynii and Analysis of Its Whole-Genome Characteristics.Transboundary and emerging diseases · 2026Article
- First Isolation of a Multi-azole-Resistant Aspergillus fumigatus cyp51A TRMycopathologia · 2025Article
- Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction inJournal of clinical microbiology · 2025Article
- Molecular Diagnostics for Invasive Molds: From Lab to Bedside.Clinics in laboratory medicine · 2025Review
- An approach to making life sciences FAIR-FAIR-DS as a tool for Aspergillus fumigatus.Database : the journal of biological databases and curation · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Insights intoJournal of fungi (Basel, Switzerland) · 2024Article
- Azole Resistance in Veterinary Clinical Aspergillus fumigatus Isolates in the Netherlands.Mycopathologia · 2024Article
- Azole resistance mechanisms and population structure of the human pathogenApplied and environmental microbiology · 2024Article
- Triazole resistance inApplied and environmental microbiology · 2024Article
- Antifungal Susceptibility and Genotypic Analysis ofInfection and drug resistance · 2024Article
- Surveillance of Amphotericin B and Azole Resistance inJournal of fungi (Basel, Switzerland) · 2023Article
- Pulmonary Aspergillosis in Humboldt Penguins-Susceptibility Patterns and Molecular Epidemiology of Clinical and EnvironmentalAntibiotics (Basel, Switzerland) · 2023Article
- 4-Allyl-2-methoxyphenol modulates the expression of genes involved in efflux pump, biofilm formation and sterol biosynthesis in azole resistantFrontiers in cellular and infection microbiology · 2023Article
- Genomic and Molecular Identification of Genes Contributing to the Caspofungin Paradoxical Effect inMicrobiology spectrum · 2022Article
- Azole Resistance andJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triazole antifungal compounds are the first treatment choice for invasive aspergillosis. However, in the last decade the rate of azole resistance among
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.